Common Technical Document (CTD) Dossier Services

Gain a regulatory advantage with X Pharma Plus CTD dossier templates, meticulously designed for the US and EU markets. Our templates cover a wide range of applications, including INDs, IMPDs, MAAs, BLAs, NDAs, and ANDAs, ensuring your documentation is compliant, accurate, and efficiently organized for successful submissions and faster approvals.

Common Technical Document (CTD) Dossier Services – Overview

Both the US and EU Health Authorities (HAs) require most regulatory applications to be submitted in the ICH-harmonized CTD format. Leveraging a structured submission approach with standardized CTD dossier templates enables efficient regulatory management, accelerated approvals, and cost-effective lifecycle management.

X Pharma Plus provides customized CTD dossier templates for a variety of regulatory applications, including INDs, IMPDs, MAAs, BLAs, NDAs, and ANDAs, tailored for pharmaceutical and biological products.

Common Technical Document (CTD) Dossier Services

“Preparation and submission of standardized regulatory dossiers for pharmaceutical product approval across global health authorities.”

X Pharma Plus CTD dossier templates are designed to streamline regulatory submissions with precision, consistency, and compliance for both pharmaceutical and biological products. Key features include:

Metadata Guidance
  • Each template is encrypted with application-specific metadata, guiding authors on Health Authority (HA) expectations for drafting content.
  • Metadata references relevant regulations, guidance documents, and best practices for US FDA and EU EMA submissions
  • Provides insights on potential challenges, including clinical hold issues, RTR risks, and CMC requirements.
User-Friendly Features
  • Pre-loaded formatting, standardized headers, titles, tables, figures, and auto-numbering for consistent data presentation.
  • Customized toolbars and styles reduce formatting time, accelerate authoring, and ensure harmonized documents.
Portability
  • Templates support the reuse of content for multiple applications, minimizing rework and facilitating lifecycle management across regions.
User Guide
  • A comprehensive, easy-to-follow user guide ensures maximum utilization of template features for efficient CTD drafting.
Application-Specific Templates
  • IND Templates (US): Author and submit INDs for Phase I–III clinical trials. Metadata guides CMC and clinical compliance, including potential clinical-hold issues.
  • IMPD Templates (EU): Support authoring and submission of IMPDs across EU member states with product-specific regulatory guidance.
  • Biologics Templates (BLA/MAA/NDA): Standardized templates for biologics submissions in the US and EU, encrypted with agency-specific metadata addressing RTR risks and application holds.
  • NDA 505(b)(2) Templates (Pharmaceuticals): Facilitate innovative filings for formulation changes, route of administration, dosing regimen, and FDC Act variations.
  • ANDA Templates: Ensure GDUFA II compliance and RTR mitigation for generic products across multiple dosage forms.
  • EU MAA Templates (Pharmaceuticals): Pre-configured for CP, MRP, DCP, and NP procedures, including regulatory guidance for tablets, capsules, solutions, suspensions, injectables, and other dosage forms.

X Pharma Plus CTD templates provide a right-first-time submission approach, significantly reducing administrative rejections, accelerating approvals, and ensuring regulatory compliance across multiple regions and applications.

  • Ensures global regulatory compliance (FDA, EMA, and other HAs).
  • Saves time and cost with pre-formatted, ready-to-use templates.
  • Delivers consistent, error-free, and harmonized submissions.
  • Supports multiple regions with portable, reusable content.
  • Minimizes risks of clinical holds, RTR, and rejections.
  • Provides user-friendly guidance and metadata-driven insights.
  • Covers all product types: IND, IMPD, BLA/MAA, NDA, ANDA, and EU MAA.
  • Accelerates approvals and speeds up market access.

Subscribe for Updates